Secondary prevention of myocardial infarction: Role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors

American Heart Journal

Volumn 137, Issue 4 II, 1999, Pages

  Frishman, W H ^a   Chengron, A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032960403     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8703(99)70393-5     Document Type: Review

References (104)

1. May GS, Furberg CD, Eberlein KA, et al. Secondary prevention after myocardial infarction: a review of short-term acute phase trials. Prog Cardiovasc Dis 1983;25:335-59.
2. May GS, Eberlein KA, Furberg CD, et al. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982;24:331-52.
3. Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction: evidence from clinical trials. N Engl J Med 1996;335:1660-7.
4. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med 1990;322:743-53.
5. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-6.
6. Davis HT, DeCamilla J, Bayer LW, et al. Survivorship patterns in the posthospital phase of myocardial infarction. Circulation 1979;60:1252-8.
7. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996;19:357-65.
8. Gheorghiade M, Ruzumna P, Borzak S, et al. Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. Am Heart J 1996;131:250-6.
9. Dellborg M, Eriksson P, Riha M, et al. Declining hospital mortality in acute myocardial infarction. Eur Heart J 1994;15:5-9.
10. Latini R, Maggioni AP, Flather M, et al, for the meeting participants. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995;92:3132-7.
11. Frishman WH, Skolnick AE, Lazar EJ, et al. β-Adrenergic blockade and calcium channel blockade in myocardial infarction. Med Clin North Am 1989;73:409-36.
12. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984;310:830-7.
13. Frishman WH, Furberg CD, Friedewald WT. The use of β-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol 1984;9:1-50.
14. Frishman WH, Sonnenblick EH. Beta-adrenergic blocking drugs. In: Schlant RC, Alexander RW, editors. Hurst's The Heart, 8th edition. New York: McGraw-Hill, Inc; 1994. p 1271-90.
15. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med 1981;305:500-6.
16. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
17. Ahlmark G, Saetre H. Long-term treatment with β-blockers after myocardial infarction. Eur J Clin Pharmacol 1976;10:77-83.
18. Ahlmark G, Saetre H, Korsgren M. Reduction of sudden deaths after myocardial infarction [Letter]. Lancet 1974;2:1563.
19. Andersen MP, Bechsgaard P, Frederiksen J, et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: preliminary results. Lancet 1979;2:865-8.
20. Australian and Swedish Pindolol Study Group. The effect of pindolol on the 2 years mortality after complicated myocardial infarction. Eur Heart J 1983;4:367-75.
21. Baber NS, Evans DW, Howitt G, et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. Br Heart J 1980;44:96-100.
22. Barber JM, Boyle DM, Chaturvedi NC, et al. Practolol in acute myocardial infarction. Acta Med Scand Suppl 1975;587:213-9.
23. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982;247:1707-14.
24. The European Infarction Study Group. European Infarction Study (EIS): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. Eur Heart J 1984;5:189-202.
25. Frommer PL, Furberg C. Beta-blocking drugs in the prevention of sudden cardiac death. In: Josephson ME, editor. Sudden Cardiac Death. Orlando: Grune & Stratton, Inc; 1985. p 249-56.
26. Furberg CD, Bell RL. Effect of β-blocker therapy on recurrent nonfatal myocardial infarction. Circulation 1983;67(suppl I):I-83-5.
27. Hansteen V, Møinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 1982;284:155-60.
28. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol: a multicentre international study. Br Med J 1975;3:735-40.
29. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for 1 year after myocardial infarction. Lancet 1982;1:1142-7.
30. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987;8:1056-64.
31. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
32. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade: multicenter international study: supplementary report. Br Med J 1977;2:419-21.
33. Taylor SH, Silke B, Ebbutt A, et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982;307:1293-301.
34. Vedin A, Wilhelmsson C, Werkö L. Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital: effects on mortality and morbidity. Acta Med Scand 1975;575(suppl):1-40.
35. Wilhelmsson C, Vedin JA, Wilhelmsen L, et al. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet 1974;2:1157-60.
36. Boissel J-P, Leizorovicz A, Picolet H, et al, for the APSI Investigators. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990;66:251-60.
37. Cruickshank JM, Prichard BNC. Myocardial infarction. In: Beta-Blockers in Clinical Practice. New York: Churchill Livingstone; 1988. p 435-504.
38. Hjalmarson Å, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;2:823-7.
39. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
40. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J 1985;6:199-226.
41. Lichstein E, Morganroth J, Harrist R, et al, for the BHAT Study Group. Effect of propranolol on ventricular arrhythmia: the β-blocker heart attack trial experience. Circulation 1983;67(suppl I):I-5-10.
42. von der Lippe G, Lund-Johansen P, Kjekshus J. Effect of timolol on late ventricular arrhythmias after acute myocardial infarction. Acta Med Scand Suppl 1981;651:253-8.
43. Nordrehaug JE, Johannessen K-A, von der Lippe G, et al. Effect oftimolol on changes in serum potassium concentrationduring acute myocardial infarction. Br Heart J 1985;53:388-93.
44. 2 receptor blockade and mortality: the BHAT experience [Abstract]. Circulation 1984;70(suppl II):II-7.
45. 2-receptor stimulation by circulating epinephrine. N Engl J Med 1983;309:1414-9.
46. Frishman WH. Multifactorial actions of β-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation 1983;67(suppl I):I-11-18.
47. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4.
48. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-40.
49. Benson RL. The present status of coronary arterial disease. Arch Pathol 1926;2:876-916.
50. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966;6:1-17.
51. Chandler AB. Mechanisms and frequency of thrombosis in the coronary circulation. Thromb Res 1974;4 (suppl 1):3-23.
52. Fulton WFM. The coronary arteries: arteriography, microanatomy, and pathogenesis of obliterative coronary artery disease. Springfield, Ill: Charles C. Thomas; 1965. p 230-300.
53. Davies MJ, Thomas T. The pathological basis and microanatomy of occlusive thrombus formation in human coronary arteries. Philos Trans R Soc Lond Biol 1981;294:225-9.
54. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-73.
55. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation 1982;66:316-20.
56. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986;7:472-8.
57. Ambrose JA, Winters SL, Stem A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609-16.
58. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985;6:1233-8.
59. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
60. Lo Y-SA, Cutler JE, Blake K, et al. Angiographiccoronary morphology in survivors of cardiac arrest. Am Heart J 1988;115:781-5.
61. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913-9.
62. Forrester JS, Litvack F, Grundfest W, et al. A perspective of coronary disease seen through the arteries of living man. Circulation 1987;75:505-13.
63. Muller JE, Toiler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
64. Shah PK. New insights into the pathogenesis and prevention of acute coronary syndrome. Am J Cardiol 1997;79(12B):17-23.
65. Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol 1990;66:66G-70G.
66. Spence JD. Effects of hydralazine versus propranolol on blood velocity patterns in patients with carotid stenosis. Clin Sci 1983;65:91-3.
67. Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood 1977;49:185-96.
68. Viskin S, Kitzis I, Lev E, et al. Treatment with betaadrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-32.
69. Zuanetti G, Latini R, Avanzini F, et al, for GISSI Investigators. Use of b-blocking agents after myocardial infarction: the GISSI experience [Abstract]. Circulation 1995;92(suppl I):I-196.
70. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274:1462-7.
71. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a review of its pharmacological properties and therapeutic potential in congestive heart failure. Drugs 1997; 54:161-85.
72. Goldman L, Sia STB, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.
73. Frishman WH. Carvedidol. N Engl J Med 1998;339:1759-65
74. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. NEngl J Med 1989;320:618-27.
75. Frishman WH. Angiotensin-converting enzyme inhibitors. In: Frishman WH, ed. Cardiovascular Drugs, 2nd ed. Current Medicine. Philadelphia: 1995. p 11-25.
76. Borek M, Charlap S, Frishman WH. Angiotensin-converting enzyme inhibitors in heart failure. Med Clin North Am 1989;73:315-38.
77. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
78. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
79. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
80. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
81. Pfeffer MA, Braunwald E, Moyé LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
82. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
83. Køber L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
84. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
85. Swedberg K, Held P, Kjekshus J, et al, on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
86. Kingma JH, van Gilst WH, Peels CH, et al, for the CATS Investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994;15:898-907.
87. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
88. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
89. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
90. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
91. Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol 1995;25:1718-25.
92. Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonism: roles in cardiovascular health and disease. Am Heart J 1995;130:601-10.
93. Cohn JN. The prevention of heart failure: a new agenda [Editorial]. N Engl J Med 1992;327:725-7.
94. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
95. Vaughan DE, Rouleau J-L, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-7.
96. Pepine CJ, Pitt B, Bertrand ME, et al. Emerging role of ACE inhibitors in vascular protection. J Myocard Isch 1995;7(suppl 1):50-8.
97. 1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 1990;258:H806-13.
98. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
99. LeJemtel TH, Hochman JS, Sonnenblick EH. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25(suppl):47S-51S.
100. Yim JM, Hoon TJ, Bittar N, et al. Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction. Am J Cardiol 1995;75:1184-6.
101. Wilson AC, Liang Z-H, Kostis J, SOLVD Study Investigators. Effect of β-blockers in patients with low ejection fractions [Abstract]. Circulation 1995;92(suppl I):1-331.
102. Kramer CM, Rogers WJ, Theobald TM, et al. β-Blockers are additive to ACE inhibitors in limiting left ventricular remodeling after first anterior myocardial infarction [Abstract]. Circulation 1995;92(suppl II):I-197.
103. Hall D, Rudolph W. Adverse effect of aspirin on water metabolism in severe heart failure treated with enalapril [Abstract]. J Am Coll Cardiol 1994;February:213A.
104. Ball SG, Hall AS, Murray GD. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. J Am Coll Cardiol 1995;25(suppl):42S-6S.